IgG antibody

Plasmodium vivax remains an important cause of malaria in South America and Asia, and analyses of the antibody immune response are being used to identify biomarker of parasite exposure. The IgG antibody naturally acquired predominantly occurs against targets on blood-stage parasites, including C-terminal of the merozoite surface protein 1 (MSP1-19). Epidemiological and immunological evidence has been showed that antibodies to malaria parasite antigens are lost in the absence of ongoing exposure.

The search for novel chemical classes of anti‐malarial compounds to cope with the current state of chemoresistance of malaria parasites, led to the identification of PfA‐M1 as a new therapeutic target. PfA‐M1, known to be involved in the hemoglobin digestion cascade which helps to provide most of the amino acids necessary to the parasite’s metabolism, is currently considered as a promising target for anti‐malarial chemotherapy.